Heliotrope Photonics, Inc. and BeneVir Biopharm are two companies that grew out of federally funded scientific research projects at New York University (NYU). The coating technology that underpins Heliotrope Photonics’ solar energy solutions was developed through research supported by the National Science Foundation (NSF). Benevir Biopharm formed from National Institutes of Health-supported research that paved
Founded in 2023, Heliotrope Photonics helps revolutionize solar energy by enhancing solar panel performance. The company’s transformative coating technology increases solar panel efficiency by up to 15%.
BeneVir Biopharm develops oncolytic immunotherapies utilizing a proprietary T-Stealth™ Oncolytic Virus Platform to engineer oncolytic viruses, tailored to infect and destroy cancer cells.
Heliotrope Photonics is in its early stages, but is poised to deliver significant economic and environmental benefits By improving solar panel efficiency, the company reduces energy costs for consumers and accelerates the adoption of renewable energy, creating opportunities for market expansion and cleantech job growth.
BeneVir Biopharm was acquired by Johnson & Johnson for $140 million upfront, with potential contingent payments of up to $900 million. Benevir exemplifies the substantial value of translating federally funded science into commercial success.
NYU serves as a critical hub for translating federally funded research into economic and societal benefits. Through its Technology Opportunities & Ventures Department, NYU enables discoveries like those behind Heliotrope Photonics and Benevir Biopharm to become market-ready innovations.